FRNM

Perceptive Capital Solutions Holdings

CIK: 0002017632

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 25, 2026

Freenome highlights CRC screening market potential. Freenome is emphasizing the large addressable market for its colorectal cancer screening test, noting it can reach 50 million patients while facing less direct competition. This narrative aims to support the company's growth outlook as the stock trades near its 52-week high range.

this person other insiders at FRNM

Transaction History

FRNM▼ Sell—
FRNM▼ Sell$2.9M

We use analytics to understand how market-wall is used. No personal data is sold.